Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04661345
Other study ID # SINOVIOMA
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date October 14, 2020
Est. completion date October 14, 2023

Study information

Verified date December 2020
Source Istituto Ortopedico Galeazzi
Contact Elena Cittera, MSc
Phone 00390266214057
Email elena.cittera@grupposandonato.it
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

One of the major causes of prosthetic joint failure is infection. Recently, coagulase-negative Staphylococci (CoNS) have been identified as emergent, nosocomial pathogens involved in subclinical prosthetic joint infections (PJIs). The diagnosis of PJIs mediated by CoNS is complex and demanding due to the absence of clear clinical signs derived from the host immune system response. In this scenario, the key to successful surgical treatment is the capability to differentiate between aseptic implant loosening and septic failure. Hence, the central hypothesis of this study is that proteomic analysis of the secretome of CoNS clinical isolates associated with the characterization of patient synovial fluids will reveal a panel of putative biomarkers tightly linked to PJIs. The confirmation of the presence of bacterial PJI biomarkers in synovial fluids of infected patients will pave the way for the development of a new reliable test capable of aiding in the diagnosis of subclinical PJIs.


Description:

Task 1.1: Synovial fluids will be collected from 60 patients referred to IRCCS Galeazzi Orthopedic Institute for the revision of a septic prosthesis and from 40 patients undergoing revision due to aseptic failure. The collected synovial fluids will be stored at -80°C until analysis. According to MSIS guidelines, the measurement of CRP and ESR levels, synovial WBC count, and the microbiological culture of the explanted device and periprosthetic tissue will be conducted following routine protocols. Only synovial fluid collected from patients of the infected group diagnosed with a PJI mediated by CoNS will be eligible for subsequent proteomic analyses. Task 1.2: The secretome of at least 10 isolates of the retrieved species of CoNS will be characterized. In particular, CoNS clinical isolates will be cultured in a drip flow reactor to induce the production of biofilm and the secretome analyzed to perform the first selection of proteins of interest. Task 2.1: Proteins extracted from the synovial fluids of patients with or without PJI will be carbamidomethylated and digested by trypsin. Thereafter, peptide mixtures will be analyzed by nano liquid chromatography coupled to tandem mass spectrometry (nano LC-MS/MS). Label-free quantifications (LFQ) will be applied to assess the levels of proteins expressed by bacteria and secreted in patient synovial fluids. Task 2.2: Using proteomic software (i.e. MaxQuant, Perseus, etc.), the bioinformatic analysis will be performed to determine a pool of proteins of interest present only in samples belonging to the infected group of patients which would be closely related to the presence of bacteria. Task 3.1: Proteins of interest identified in Task 1.2 and Task 2.2 as putative biomarkers related to CoNS-mediated PJIs will be selected for targeted proteomic analyses by means of additional bioinformatic analyses. Task 3.2: To confirm the presence of putative biomarkers defined in Task 3.1 in synovial fluid of enrolled patients, targeted proteomic analysis will be performed on all the infected/not infected samples collected in Task 1.1. Prototypic peptides for each putative biomarker will be selected by Skyline software. Ionization and fragmentation behaviors of all candidate peptides will be studied. Task 3.3: Finally, the information from the targeted proteomic analysis will be correlated to the outcomes of the diagnosis formulated following the MSIS guidelines in order to evaluate the diagnostic value of each selected biomarker.


Recruitment information / eligibility

Status Recruiting
Enrollment 100
Est. completion date October 14, 2023
Est. primary completion date September 14, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - = 18 years old patients - Patients subjected to a revision of the articular prosthesis due to bacterial infection mediated by coagulase-negative Staphylococci (CoNS) or to an aseptic failure of the implant - Collection of a sufficient volume of synovial fluid - Patient consent by signing an informed consent form Exclusion Criteria: - Patients not fulfilling the inclusion criteria - Collection of a hemolytic sample

Study Design


Intervention

Other:
Proteomic analysis of synovial fluids
Characterization of the proteome of infected/aseptic synovial fluid for the identification of molecular hallmarks strictly related to the presence of a bacterial infection mediated by coagulase-negative Staphylococci
Proteomic analysis of the isolated coagulase-negative Staphylococci
Characterization of the secretome of coagulase-negative Staphylococci isolated from infected prosthetic implants

Locations

Country Name City State
Italy IRCCS Istituto Ortopedico Galeazzi Milan

Sponsors (1)

Lead Sponsor Collaborator
Istituto Ortopedico Galeazzi

Country where clinical trial is conducted

Italy, 

Outcome

Type Measure Description Time frame Safety issue
Primary Identification of molecular hallmarks strictly related to the presence of coagulase-negative Staphylococci in synovial fluids Characterization of the synovial fluids of septic/aseptic enrolled patients for the identification of a pool of protein of interest strictly related to the presence of coaglase-negative Staphylococci 3 years
Secondary Proteomic analysis of coagulase-negative Staphylococci Characterization of the secretome of CoNS clinical isolate, and the characterization of the proteome of the synovial fluids of septic/aseptic enrolled patients 3 years
See also
  Status Clinical Trial Phase
Completed NCT04067843 - Effect of Photodynamic Treatment on Skin Microbiome. Single Center Study N/A
Enrolling by invitation NCT05247281 - NGS vs Culture Outcomes for Treatment of PJI N/A
Withdrawn NCT05269121 - Bacteriophage Therapy in First Time Chronic Prosthetic Joint Infections Phase 1/Phase 2
Recruiting NCT02801253 - Cohort of Prosthetic Joint Infections
Completed NCT03694925 - Diagnostic Utility of a Novel Point-of-Care Test of Calprotectin for Revision Total Knee Arthroplasty
Completed NCT03721328 - Safety and Efficacy in Patients Treated for Hip or Knee PJI With Vancomycin and Tobramycin Joint Irrigation Phase 2
Withdrawn NCT04787250 - Bacteriophage Therapy in Patients With Prosthetic Joint Infections Phase 1/Phase 2
Recruiting NCT03307109 - Quality of Life in Patients Having a Prosthetic Joint Infection
Recruiting NCT02805803 - Quality of Life Assessment in Patients Undergoing Prolonged Suppressive Antibiotherapy for Prosthetic Joint Infection. N/A
Completed NCT02413034 - The Influence of Antibiotic Prophylaxis on Intraoperative Prosthetic Joint Infection Cultures N/A
Recruiting NCT03784807 - New Strategies for Biofilm Related Infections
Completed NCT04662632 - Abbreviated Protocol for Two-Stage Exchange Phase 2
Not yet recruiting NCT04390607 - Leukocyte Esterase Sensor Test
Recruiting NCT04650607 - Phage Safety Cohort Study
Active, not recruiting NCT04946500 - Clindamycin in Prosthetic Joint Infections Caused by Staphylococcus (CISTA)
Recruiting NCT04762706 - Measuring Distress in Prosthetic Joint Infection Using a Standardized Metric: CRUTCH Pathway Pilot. N/A
Withdrawn NCT05269134 - Bacteriophage Therapy in Patients With Prosthetic Joint Infections (PJI) Phase 2
Not yet recruiting NCT05239312 - Antibiogram and Biofilm Formation of Bacteria Causing Prosthetic Joint Infections Isolated From Assiut University Hospital
Completed NCT04294862 - Tissue Distribution, Pharmacokinetics, Safety, and Tolerability After a Single Dose of TNP-2092 in Participants Undergoing Primary Total Hip or Knee Arthroplasty Phase 1
Recruiting NCT05060952 - Calprotectin in Chronic Prosthetic Joint Infection